NCT00564148

Intravitreal Avastin in Proliferative Retinopathies

Intravitreal Injections With Avastin in Proliferative Retinopathies Related to the Production of VEGF Having Different Causes

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Ophthalmological Association Edelweiss · Academic / Other
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

The study intends to assess the effect of Avastin injections in different proliferative retinopathies due to different causes

Detailed description

Proliferative retinopathies due to different causes represent important causes for the visual acuity loss. Conventional treatments may sometimes improve the visual function, whereas other times, the visual acuity continue to decrease, in spite of all the medical, surgical or laser treatments. Intravitreal injections with anti-VEGF agents (ex. Avastin for our trial) seem to be an important tool for certain difficult situations in which at the ocular fundus, out of different reasons (advanced age, diabetes mellitus, retinal veins occlusions, etc)new pathologic vessels appear, causing devastating changes in the posterior and anterior segment as well.

Conditions

• Retinal Neovascularization

Interventions

Type	Name	Description
DRUG	Avastin	2,5 mg Avastin intravitreal injections every 4 weeks, 6 months consecutively

Timeline

• Start date: 2007-07-01
• Primary completion: 2009-11-01
• Completion: 2009-12-01
• First posted: 2007-11-27
• Last updated: 2011-07-22

Locations

1 site across 1 country: Romania